TheraRadar
← Back
Data updated: Jun 28, 2026

NESHER PHARMS

Generics

NESHER PHARMS is a generic drug manufacturer focused on Cardiovascular, Infectious Disease.

1980
Since
24
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

NESHER PHARMS's Key Drugs

NESHER PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NESHER PHARMS's Recent FDA Approvals

New NDA/BLA approvals for NESHER PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NESHER PHARMS's Therapeutic Areas

NESHER PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 67%
2 drugs
Infectious Disease 33%
1 drugs

NESHER PHARMS's Top Competitors

NESHER PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NESHER PHARMS Pipeline Snapshot

Active clinical trials for NESHER PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling